

1    **Absolute Quantification of Nanoparticle Interactions with Individual Human B Cells by**  
2    **Single Cell Mass Spectrometry**

3

Nathan D. Donahue<sup>1</sup>, Vinit Sheth<sup>1</sup>, Alex N. Frickenstein<sup>1</sup>, Alyssa Holden<sup>1</sup>, Sandy Kanapilly<sup>2</sup>,  
Chady Stephan<sup>3</sup>, and Stefan Wilhelm<sup>\*1,4,5</sup>

<sup>1</sup> Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma,  
73019, USA

<sup>2</sup> PerkinElmer, Waltham, MA, 02451, USA

<sup>3</sup> PerkinElmer, Woodbridge, ON, L4L8H1, Canada

<sup>4</sup> Institute for Biomedical Engineering, Science, and Technology (IBEST), Norman, Oklahoma,  
73019, USA

<sup>5</sup> Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, USA

\* Corresponding author:      Stefan Wilhelm, Ph.D.

Email:                            [stefan.wilhelm@ou.edu](mailto:stefan.wilhelm@ou.edu)


ORCIDs of authors:

Nathan D. Donahue            0000-0003-0251-0226

Sandy Kannapilly            0000-0003-3840-1910

4    Stefan Wilhelm            0000-0003-2167-6221

1 Graphical Abstract



1    **Abstract**

2    We report on the absolute quantification of nanoparticle interactions with individual human B cells  
3    using quadrupole-based inductively coupled plasma mass spectrometry (ICP-MS). This method  
4    enables the quantification of nanoparticle-cell interactions at single nanoparticle and single cell  
5    levels. We demonstrated the efficient and accurate detection of individually suspended B cells and  
6    found a ~100-fold higher association of colloidally stable positively charged nanoparticles with  
7    single B cells than neutrally charged nanoparticles. We confirmed that these nanoparticles were  
8    internalized by individual B cells and determined that the internalization occurred via energy-  
9    dependent pathways consistent with endocytosis. Using dual analyte ICP-MS, we determined that  
10   >80% of single B cells were positive for nanoparticles. Our study demonstrated an ICP-MS  
11   workflow for the absolute quantification of nanoparticle-cell interactions with single cell and  
12   single nanoparticle resolution. This unique workflow could inform the rational design of various  
13   nanomaterials for controlling cellular interactions, including immune cell-nanoparticle  
14   interactions.

1    **Keywords**

2    Nanoparticle, B cell, Nano-Bio Interactions, Single-Cell ICP-MS, Elemental Analysis, Mass

3    Spectrometry

1 Engineered nanoparticles can deliver antigens and nucleic acid-based payloads for immune  
2 system activation to induce safe and durable immune responses.<sup>1-3</sup> This activation process often  
3 includes B cells that mediate antibody-dependent responses and assist with long-lasting  
4 immunity.<sup>4-6</sup> Nanoparticles may interact with B cells in organs and tissues, such as the liver,  
5 spleen, and lymph nodes, impacting nanoparticle delivery efficiency, activity, fate, and toxicity.<sup>7-</sup>  
6<sup>12</sup> To develop safe and effective nanoparticle formulations for immune system activation, there is  
7 a need to quantify the interactions between nanoparticles and immune cells, such as individual B  
8 cells, at the single cell level.

9 Typically, flow cytometry provides single cell analysis of nanoparticle-cell interactions.  
10 However, in flow cytometry, nanoparticles may require fluorophores that can alter a nanoparticle's  
11 physicochemical properties, therefore often affecting cellular association and uptake.<sup>13,14</sup>  
12 Fluorophore-free measurements with flow cytometry using light scattering of cells exposed to  
13 nanoparticles have been performed but rely on nanoparticles >20 nm in size (Table S1).<sup>15-17</sup>  
14 Similarly, microscopy-based analyses of nanoparticle-cell interactions are often limited by  
15 fluorescence and typically exhibit low-throughput (Table S1).<sup>18,19</sup>

16 By contrast, mass spectrometry methods (e.g., CyTOF) have been applied to examine  
17 nanoparticle-cell interactions at the single cell level with multi-element capabilities used for deep  
18 phenotyping of diverse cell populations (Table S1).<sup>20-22</sup> As an economical alternative to these  
19 existing techniques, quadrupole-based inductively coupled plasma mass spectrometry (ICP-MS)  
20 is a promising method for quantifying nanoscale interactions.<sup>23</sup> Researchers have used single cell  
21 ICP-MS (SC-ICP-MS) to probe nanoparticle interactions with algae, yeast, and bacteria.<sup>24-27</sup> Other  
22 studies using SC-ICP-MS investigated intrinsic metals, metallodrugs, and nanoparticles within  
23 various human cell lines.<sup>28-31</sup> In this report, we demonstrated that quadrupole SC-ICP-MS detected

1 metal-tagged human B cells at a rate of ~30 cells per second with a 50% transport efficiency. We  
2 quantified model gold nanoparticles (AuNPs) within single B cells and further demonstrated that  
3 >80% of B cells had internalized AuNPs.

4 We first sought to compare two different cell labeling methods to count individual B cells with  
5 SC-ICP-MS accurately. The first method relied on an iridium-based DNA intercalator, commonly  
6 used in mass cytometry to non-specifically mark nucleated single cells (Figure 1A).<sup>32</sup> The second  
7 cell labeling method use streptavidin-coated quantum dots that selectively bind to specific biotin-  
8 conjugated anti-human CD19 monoclonal antibodies (Figure 1B). We hypothesized that, in  
9 contrast to the iridium staining, quantum dot labeling of B cells would generate a stronger ion  
10 signal per cell once the cells were atomized and ionized by the argon-based ICP (Table S2, Figure  
11 S1). To test this hypothesis, we prepared a single cell suspension of B cells that were stained with  
12 the iridium intercalator (Figure 1A). Additionally, we prepared B cells labeled with commercially  
13 available 15-nm streptavidin-coated Cd-based quantum dots consisting of a CdSe core and a ZnS  
14 shell and exhibiting an emission maximum of ~655 nm (Figure S2). To label B cells with  
15 streptavidin-modified quantum dots, we leveraged the ubiquitous surface expression of CD19.<sup>33,34</sup>  
16 First, we incubated B cells with biotinylated anti-human CD19 monoclonal antibodies and then  
17 used streptavidin-coated Cd-based quantum dots to selectively bind to the biotinylated B cells  
18 (Figure 1B).<sup>35,36</sup> To confirm the specific binding properties of streptavidin-coated quantum dots to  
19 biotinylated antibodies, we prepared mixtures of quantum dots with and without biotinylated anti-  
20 CD19 antibodies and quantified the corresponding <sup>114</sup>Cd signals using single particle ICP-MS (SP-  
21 ICP-MS) following previous SP-ICP-MS techniques.<sup>23,37</sup> Using SP-ICP-MS, we observed a five-  
22 fold enhancement of <sup>114</sup>Cd intensity for streptavidin quantum dots mixed with biotinylated anti-  
23 CD19 antibodies when compared to quantum dots alone (Figure S3). These SP-ICP-MS results

1 indicated successful clustering of streptavidin-coated quantum dots with biotinylated anti-CD19  
2 antibodies. Additionally, we used fluorescence-based confocal laser scanning microscopy (CLSM)  
3 to confirm the surface labeling of B cells with the fluorescent quantum dots in the presence of anti-  
4 human CD19 monoclonal antibodies (Figure S4).

5 We then quantified the corresponding transient ion signals of individual iridium- and quantum  
6 dot-labeled B cells, respectively (Figure 1C,D). Iridium-stained B cells produced transient  $^{193}\text{Ir}$   
7 signals with  $\sim$ 15 counts (Figure 1C), while quantum dot labeled B cells produced transient  $^{114}\text{Cd}$   
8 signals with  $\sim$ 42 counts (Figure 1D). These transient ion signals and corresponding counts  
9 indicated that quantum dot labeling of B cells enhanced the ion signal of individual B cells  $\sim$ 3-  
10 fold. These observations were consistent with the expected larger number of ions obtained from a  
11 single B cell labeled with 15-nm Cd-based quantum dots compared to the iridium staining. Our  
12 demonstrated quantum dot-based labeling of individual cells in combination with biotinylated  
13 antibodies that recognize specific cell surface markers represents a potentially generalizable  
14 method to identify a particular type of cell for a given heterogeneous biological sample to analyze  
15 nanoparticle-cell interactions using the described quadrupole-based SC-ICP-MS workflow.

16 We then sought to confirm that intact and individual B cells entered the ICP-MS (Figure S1).  
17 To confirm this, we sequentially measured  $^{114}\text{Cd}$  and  $^{193}\text{Ir}$  events with SC-ICP-MS at various B  
18 cell concentrations obtained from a suspension of single B cells. Figures S5 and S6 show the  
19 hemocytometer images of B cells obtained from stock single cell suspensions. We observed that  
20 both  $^{114}\text{Cd}$  and  $^{193}\text{Ir}$  provided similar detected events at equivalent cell concentrations using SC-  
21 ICP-MS (Figure 1E). Next, we confirmed that these detected events corresponded to single intact  
22 B cells with epifluorescence microscopy. Figure S7 confirms that B cells remained intact upon  
23 nebulization and entry into the ICP-MS. Image analysis corroborated these findings and revealed

1 Pearson correlation values of 0.9 pre- and post-nebulization for the B cell membranes and nuclei.  
2 Taken together, these results indicate that intact B cells entered the ICP-MS and were accurately  
3 detected with single cell resolution using SC-ICP-MS.

4 Based on the  $^{114}\text{Cd}$  and  $^{193}\text{Ir}$  events in Figure 1E, we calculated the cellular transport efficiency  
5 using equation S1 (Figure 1F). The cellular transport efficiency enabled us to determine how many  
6 cells were detected upon entry into the ICP-MS, which we then applied to quantify the mass of  
7 various isotopes in individual B cells.<sup>38</sup> Using Equation S1, we found that the B cell transport  
8 efficiency was ~50% for both iridium staining and quantum dot labeling procedures at all cell  
9 concentrations used. Our results are significant since typical transport efficiencies for SC-ICP-MS  
10 are between 1-5%, with a throughput lower than ten cells per second.<sup>39-41</sup>

11 We validated these results with commercially available micron-sized lanthanide-doped  
12 polymer beads as a model system for single cells.<sup>24,42</sup> At similar concentrations as the B cells,  
13 single lanthanide-doped beads were detected at a rate of ~40 events per second, yielding a transport  
14 efficiency of ~60% (Figure S8), representing the upper limit for this technique. We emphasize that  
15 with (i) microsecond detector dwell times: (ii) sample flow rates of 13.0  $\mu\text{L}/\text{minute}$ , (iii) cell  
16 concentrations  $\leq 3 \times 10^5$  cells/mL, (iv) 50% transport efficiency, and (v) single cell suspensions with  
17 intact B cells (Figures S5, S6, and S7), the probability of measuring overlapping/multiple cell  
18 events was minimized below a probability of 0.05 per Poisson statistics.<sup>43</sup> Collectively, these  
19 results confirmed consistent detection of intracellular and surface-bound metals on single and  
20 intact B cells with SC-ICP-MS. Based on these results, we then sought to quantify nanoparticle  
21 interactions at the single B cell level.

22 To model nanoparticle interactions with single B cells, we synthesized 13-nm quasi-spherical  
23 AuNPs with a narrow size distribution and tunable surface chemistry.<sup>44</sup> Using our previously

1 established SP-ICP-MS method, we determined that 93% of the in-house synthesized AuNPs had  
2 a mass of ~24 ag, corresponding to an AuNP diameter of ~13 nm assuming a spherical geometry  
3 (Figure S9).<sup>37</sup> Transmission electron microscopy and dynamic light scattering measurements  
4 corroborated these SP-ICP-MS findings (Figures S10 and Table S3).

5 To probe how nanoparticle surface charge impacted interactions with individual B cells, we  
6 prepared 13-nm AuNPs with two different surface modifications according to previously published  
7 protocols: (ii) neutral methoxy-terminated poly(ethylene glycol), mPEG, (1 kDa), or (ii) positively  
8 charged peptide (K7C) with a similar molecular weight as the 1 kDa mPEG.<sup>45</sup> These surface  
9 modifications yielded 13-nm AuNPs with similar hydrodynamic diameters but with a zeta  
10 potential difference of ~18 mV (Table S3). These nanoparticles with two different surface charges  
11 provided model systems to probe nanoparticle interactions with B cells. To ensure that the surface  
12 modifications did not compromise nanoparticle colloidal stability, we measured the mass of  
13 individual surface-modified 13-nm AuNPs under conventional cell culture conditions at 37°C. Our  
14 SP-ICP-MS data showed that the most frequent and average masses for both surface-modified  
15 AuNPs remained at ~24 ag, which indicated that the surface modifications did not result in  
16 detectable nanoparticle agglomeration (or aggregation) (Figure S11).<sup>37</sup>

17 We hypothesized that positively charged AuNPs modified with K7C peptides containing seven  
18 lysine residues would associate more strongly with individual B cells than AuNPs modified with  
19 neutral mPEG potentially due to favorable electrostatic interactions with the overall negatively  
20 charged cell membrane.<sup>46</sup> We used SC-ICP-MS to quantify the average amount of <sup>197</sup>Au associated  
21 per individual B cell upon exposure to the differently charged 13-nm AuNPs under the same  
22 exposure conditions (Figure 2A). For B cells exposed to mPEG-modified AuNPs, the average  
23 <sup>197</sup>Au mass per cell was 315 ag, corresponding to ~13 AuNPs per cell. Conversely, B cells treated

1 with the same molar concentration of K7C peptide-modified 13-nm AuNPs exhibited an average  
2  $^{197}\text{Au}$  mass of 30,117 ag per cell, corresponding to  $\sim$ 1,250 AuNPs per cell. These results showed  
3 that peptide-modified AuNPs were nearly two orders of magnitude more effective in associating  
4 with individual B cells than the neutral mPEG-modified AuNPs. We then obtained the single cell  
5  $^{197}\text{Au}$  mass distribution of B cells exposed to either 13-nm mPEG-modified AuNPs or 13-nm K7C-  
6 modified AuNPs (Figure 2B). Interestingly, the most frequent mass of B cells exposed to mPEG-  
7 modified AuNPs was  $\sim$ 24 ag, the same mass of a single 13-nm AuNP (Figures S9 and S11). Only  
8 4% of the total  $^{197}\text{Au}$  events were above 24 ag for B cells exposed to 13-nm mPEG-modified  
9 AuNPs with a maximum detected mass of 13,000 ag per cell. On the other hand,  $\sim$ 95% of  $^{197}\text{Au}$   
10 events were above 24 ag for B cells exposed to 13-nm K7C-modified AuNPs. We measured a  
11 maximum  $^{197}\text{Au}$  mass of 50,000 ag per cell, the maximum mass the SC-ICP-MS instrument could  
12 detect for these conditions. Collectively, our quantitative SC-ICP-MS results indicated that K7C-  
13 modified AuNPs enhanced B cell nanoparticle association on average  $\sim$ 100-fold compared to  
14 mPEG-AuNPs.

15 We then qualitatively assessed nanoparticle association with B cells with CLSM using a label-  
16 free light scattering approach to visualize AuNPs associated with B cells.<sup>47,48</sup> Due to the ability of  
17 metallic nanoparticles to scatter light, fluorophores were not required to visualize AuNPs.  
18 Interestingly, only B cells exposed to K7C-modified AuNPs had detectable intracellular CLSM  
19 light scattering signals (Figure 2C). On the other hand, B cells exposed to mPEG-modified AuNPs  
20 (Figure 2D) lacked detectable CLSM light scattering signals, similar to B cells without AuNPs  
21 (Figures 2E). These qualitative label-free CLSM-based imaging results corroborated the SP-ICP-  
22 MS results and demonstrated how nanoparticle surface charge governed nanoparticle interactions  
23 with individual B cells. To assess the biocompatibility of the K7C-modified AuNPs, we evaluated

1 the viability of B cells exposed to several different concentrations of K7C-modified AuNPs with  
2 a colorimetric viability assay (Figure S12). The assay confirmed that our cationic peptide-modified  
3 AuNPs were a safe model for further investigating nanoparticle-cell interactions at the single B  
4 cell level.

5 Previous studies used KI/I<sub>2</sub> etching to remove extracellular AuNPs in cell culture  
6 experiments.<sup>49</sup> We wondered whether this approach could be adopted for quantifying internalized  
7 vs. associated AuNPs at the single B cell level. We confirmed that upon exposure to KI/I<sub>2</sub> etchant  
8 solution, 13-nm AuNPs were undetectable by dynamic light scattering (DLS) and no longer  
9 exhibited the characteristic surface plasmon resonance-based absorption properties using UV-Vis  
10 spectrophotometry, thus indicating the dissolution of the AuNPs (Table S4 and Figure S13). To  
11 visualize nanoparticle uptake within B cells, we first examined B cells exposed to AuNPs with and  
12 without KI/I<sub>2</sub> etchant using CLSM. To help identify internalized AuNPs, we tracked intracellular  
13 vesicles with fluorescently-modified dextran and acquired CLSM Z-stacks of B cells exposed to  
14 13-nm K7C peptide-modified AuNPs (Figure 3A).<sup>50</sup> The representative Z-projection in Figure 3A  
15 shows colocalization between AuNP scattering signal and fluorescently labeled intracellular  
16 vesicles. Upon exposing B cells to KI/I<sub>2</sub> etchant, the nanoparticles were still localized within  
17 intracellular vesicles (Figures 3B). Our CLSM images indicated that B cells internalized  
18 nanoparticles within intracellular vesicles, and that these internalized nanoparticles did not degrade  
19 upon KI/I<sub>2</sub> etchant exposure.

20 We then used SC-ICP-MS to quantify the number of internalized AuNPs per individual B cell.  
21 We first obtained the average <sup>197</sup>Au mass of B cells exposed to 13-nm K7C peptide-modified  
22 AuNPs with and without KI/I<sub>2</sub> etchant treatment (Figure 3D). The average <sup>197</sup>Au mass decreased  
23 by ~3,000 ag after the B cells were exposed to KI/I<sub>2</sub> etchant, indicating that only ~125 AuNPs had

1 been etched away. These results were validated by CLSM imaging and suggested that K7C  
2 peptide-modified AuNPs were engulfed by cells instead of adhering to the B cell membrane. To  
3 confirm the KI/I<sub>2</sub> etchant's ability to remove surface-bound AuNPs, we exposed B cells to K7C  
4 peptide-modified AuNPs at 4°C. This temperature reduces a cell's membrane fluidity and  
5 effectively inhibits nanoparticle endocytosis.<sup>46</sup> We observed that the B cells kept at 4°C exhibited  
6 an average of ~10,000 ag of associated <sup>197</sup>Au corresponding to ~417 AuNPs per cell. However,  
7 after the cells were exposed to the KI/I<sub>2</sub> etchant, the number of <sup>197</sup>Au events decreased and over  
8 9,000 ag of <sup>197</sup>Au (~375 AuNPs) were removed per B cell (Figure 3C).

9 Similarly, B cells that were fixed with 4% paraformaldehyde before exposure to K7C peptide-  
10 modified AuNPs exhibited an average of ~10,000 ag of associated <sup>197</sup>Au per individual B cell.  
11 Upon KI/I<sub>2</sub> etchant exposure, these fixed B cells lost over 9,000 ag of <sup>197</sup>Au per individual B cell.  
12 Our SC-ICP-MS data showed that although K7C peptide-modified AuNPs efficiently associated  
13 with B cells, approximately 95% of extracellular AuNPs could be removed upon chemical etching.  
14 These results were further corroborated by the mass distribution of single B cells before and after  
15 KI/I<sub>2</sub> etching (Figure 3E). Our KI/I<sub>2</sub> etching results revealed that K7C peptide-modified AuNPs  
16 accumulated inside B cells through energy-dependent mechanisms, likely endocytosis, which we  
17 quantified at the single cell level with SC-ICP-MS.

18 Since quadrupole SC-ICP-MS is limited to detecting one element per cell event, cells without  
19 AuNPs were not detected. To overcome this limitation, we sought to simultaneously analyze a cell  
20 marker and AuNPs using our previously established dual analyte quadrupole ICP-MS technique.<sup>23</sup>  
21 Briefly, transient ion signals of analytes are elongated, allowing the quadrupole mass filter to  
22 switch between two different isotopes per event efficiently. First, we compared transient ion  
23 signals of iridium-stained B cells and quantum dot labeled B cells under conditions that enable the


1 simultaneous detection of two isotopes per event on quadrupole ICP-MS (Table S5). Figure 4A  
2 shows that the transient ion cloud for quantum dot labeled B cells extends up to 5 ms with a  
3 maximum intensity of ~35 counts, whereas the iridium-stained B cells had 5-fold fewer counts and  
4 barely lasted 2 ms (Figure 4A). B cells exposed to K7C peptide-modified AuNPs exhibited  
5 transient  $^{197}\text{Au}$  signal durations >5 ms with intensities over 100 counts under optimized dual  
6 analyte ICP-MS conditions (Figure S14). These millisecond transient ion signals pointed to the  
7 possibility of efficient quadrupole mass filter switching between a cell marker and internalized  
8 AuNPs, thus enabling the simultaneous detection of B cells that were positive or negative for  
9 AuNPs using quadrupole ICP-MS. We found that only quantum dot labeled B cells enabled the  
10 accurate simultaneous determination of individual B cells that had internalized AuNPs in dual  
11 analyte SC-ICP-MS mode (Figure 4B). When  $^{114}\text{Cd}$  and  $^{197}\text{Au}$  were measured sequentially (i.e.,  
12 one isotope at a time)  $81.1 \pm 8.9\%$  of B cells were positive for AuNPs (i.e.,  $\text{AuNP}^+$ ). Similarly,  
13 when  $^{114}\text{Cd}$  and  $^{197}\text{Au}$  were measured simultaneously (i.e., both isotopes detected simultaneously  
14 under optimized dual analyte SC-ICP-MS conditions),  $79.6 \pm 11.1\%$  of B cells were  $\text{AuNP}^+$ . We  
15 only found similar results when  $^{193}\text{Ir}$  and  $^{197}\text{Au}$  were measured sequentially ( $83.2 \pm 6.1\%$ , Figure  
16 4C). However, when  $^{193}\text{Ir}$  and  $^{197}\text{Au}$  were measured simultaneously, the number of  $^{193}\text{Ir}$  events  
17 decreased by ~50% (Figure 4C). These results indicated that although iridium staining of  
18 individual B cells worked well for the detection of single cells in single analyte mode on  
19 quadrupole-based SC-ICP-MS, the high signal intensity and long millisecond transient ion signals  
20 from quantum dot nanoparticles and AuNPs were needed for the accurate simultaneous  
21 measurement of two different analytes in a single cell.

22 We corroborated our dual analyte SC-ICP-MS results with CLSM imaging and showed that B  
23 cells labeled with quantum dots and exposed to K7C peptide-modified AuNPs could be visualized


1 (Figure 4D). To provide a better understanding of how many B cells had AuNPs, we counted 96  
2 representative quantum dot-labeled B cells from multiple fields of view and determined that 83 of  
3 those cells exhibited AuNP scattering intensity, indicating that ~87% of B cells had internalized  
4 AuNPs (Figure 4E).

5 In conclusion, we showed that B cells labeled with either an intracellular (DNA) stain (iridium)  
6 or surface-bound labels (quantum dots) enabled the detection and quantification of individual B  
7 cells using quadrupole SC-ICP-MS at a maximum rate of ~30 cells per second. We quantified the  
8 AuNP association with B cells at the single cell level and observed that positively charged AuNPs  
9 safely enhanced B cell association ~100-fold compared to neutral charged AuNPs. We further  
10 demonstrated the ability to quantify internalized AuNPs with SC-ICP-MS and showed that these  
11 nanoparticles entered B cells through active internalization pathways. Lastly, we determined that  
12 >80% of B cells had internalized AuNPs by using quantum dot labeling in combination with a  
13 quantitative dual analyte SC-ICP-MS workflow and corroborated the findings with label-free light  
14 scattering-based CLSM imaging. The demonstrated SC-ICP-MS workflow could potentially be  
15 adopted and expanded to quantify nanoparticle-cell interactions with organic nanoparticles bearing  
16 metal tags. Our established SC-ICP-MS workflow provides a quantitative framework for  
17 researchers who seek to understand nanoparticle-cell interactions at the single cell level with far-  
18 reaching implications for nano ecology, nanotoxicology, and nanomedicine, including  
19 nanovaccines.


1 **Figures**




2  
3 **Figure 1: Detection of individual metal-labeled B cells.** (A) Schematic representation of nucleic acid intercalator staining with natural-abundance iridium of individual B cells. (B) Schematic representation of labeling individual B cells with cadmium-based streptavidin-conjugated quantum dots via biotinylated Anti-CD19 antibodies. (C) Transient  $^{193}\text{Ir}$  ion signal of individual iridium-stained B cells. (D) Transient  $^{114}\text{Cd}$  ion signal of individual cadmium-based quantum dot labeled B cells. (E) Detected cell events as a function of cell concentration for  $^{114}\text{Cd}$  ( $r^2=0.99$ ) and  $^{193}\text{Ir}$  ( $r^2=0.99$ ). Symbols represent averages and standard deviations of 3 independent experiments. Scan time = 30 s. (F) Transport efficiencies of individual B cells based on detected events from (E) and calculated using Equation 1. Symbols represent averages and standard deviations of three independent experiments. The total acquisition scan time was 30 seconds for each measurement.



1  
2 **Figure 2: Quantifying and visualizing nanoparticle-cell association at the single-cell level. (A)**  
3 The Average  $^{197}\text{Au}$  masses obtained from B cells exposed to 13-nm K7C AuNPs, 13-nm mPEG  
4 AuNPs, or no AuNPs for 12 h. Circles represent the average  $^{197}\text{Au}$  mass of  $\geq 500$   $^{197}\text{Au}$  events.  
5 Bars represent the average of 3 independent experiments. **(B)** Mass distribution of B cells exposed  
6 to either 13-nm K7C conjugated AuNPs (green), 13-nm mPEG conjugated AuNPs (orange), or no  
7 AuNPs (pink) for 12 h. Confocal laser scanning microscopy images of B cells exposed for 12 h to  
8 13-nm K7C-modified AuNPs **(C)**, 13-nm mPEG-modified AuNPs **(D)**, and without AuNPs **(E)**.  
9 Scale bars represent 20  $\mu\text{m}$ . The white arrows in **(C)** indicate the location of AuNPs.  
10



1  
2  
3 **Figure 3: Visualizing and quantifying nanoparticle interactions with individual B cells. (A-C)** Confocal laser scanning microscopy (CLSM) maximum intensity projections (MIP) of B cells  
4 exposed to 13-nm AuNPs surface-modified with K7C peptides for 8 h without (A) and with (B)  
5 exposure to KI/I<sub>2</sub> etchant that dissolves AuNPs. (C) CLSM maximum intensity projection (MIP)  
6 images of B cells without AuNPs exposure (cell only control group). Scale bar represents 20  $\mu$ m.  
7 The intracellular vesicles were labeled with fluorescently-tagged dextran. (D) Average <sup>197</sup>Au  
8 masses of individual B cells exposed to 13-nm AuNPs surface-modified with K7C peptides under  
9 different conditions for 8 h without etchant (blue) and with an etchant (red). Circles represent the  
10 average <sup>197</sup>Au mass of  $\geq 500$  <sup>197</sup>Au events. Bars represent the averages of three independent  
11 measurements. Unpaired T-Test was used to determine the statistical significance between the  
12 average <sup>197</sup>Au mass before and after etching (n.s. - no significance; \*\*\* p  $\leq 0.001$ , \*\*\*\* p  $\leq 0.0001$ )  
13 (E) The <sup>197</sup>Au mass distribution based on individual B cells exposed to 13-nm AuNPs surface-  
14 modified with K7C peptides without etchant (blue) and with an etchant (red).  
15



**Figure 4: Determining AuNP<sup>+</sup> B cells with dual-analyte SC-ICP-MS. (A)** Transient ion peak shapes of cadmium and iridium labeled B cells using optimized dual-analyte SC-ICP-MS conditions to detect <sup>193</sup>Ir and <sup>114</sup>Cd. **(B)** SC-ICP-MS determination of AuNP<sup>+</sup> B cells with sequential and simultaneous analysis of <sup>193</sup>Ir and <sup>197</sup>Au in individual B cells exposed to 13-nm AuNPs surface-modified with K7C peptides for 8 h. Bars represent mean values with standard deviations from three independent measurements. **(C)** SC-ICP-MS determination of AuNP<sup>+</sup> B cells using sequential and simultaneous analysis of <sup>114</sup>Cd and <sup>197</sup>Au in individual B cells exposed to 13-nm AuNPs surface-modified with K7C peptides for 8 h. Bars represent mean values with standard deviations from three independent measurements. Unpaired T-Test was used to determine the statistical significance between events detected with sequential measurements or simultaneous measurements of cell markers and AuNPs (n.s.- no significance; \*\* p ≤ 0.01) **(D)** Representative confocal laser scanning microscopy (CLSM) images of B cells exposed to 13-nm AuNPs surface-modified with K7C peptides for 8 hours and labeled with streptavidin-coated quantum dots via biotinylated anti-CD19 antibodies. Images i-v display different emission channels. Scale bar represents 20 μm. **(E)** The number of quantum dot labeled B cells (quantum dot (+)) and AuNPs<sup>+</sup> cells. The numbers were obtained using representative CLSM images (40x objective) with AuNP scattering intensity from multiple fields of view.

1    **Acknowledgments**

2    The authors acknowledge the assistance of Drs. S. Foster, P. Larson, J. Sabisch, S. Liang., B.  
3    Fowler, and J. Willige. Additionally, the authors acknowledge the University of Oklahoma (OU)  
4    Samuel Roberts Noble Microscopy Laboratory (SRNML), the OU Mass Spectrometry, Proteomics  
5    & Metabolomics (MSPM) Core, and the Oklahoma Medical Research Foundation (OMRF)  
6    Imaging Core Facility for assistance. The authors thank Drs. Irvine and Melo for kindly providing  
7    the Raji cell line. This work was supported in part by an NSF MRI grant (1828234), NSF CAREER  
8    award (2048130), an NIH COBRE award (P20GM135009), an IBEST/OUHSC seed grant for  
9    interdisciplinary research, the OU VPRP Strategic Equipment Investment grant, the OU Faculty  
10   Investment Program, an OCAST Health Research grant (HR20-106), and the Oklahoma Tobacco  
11   Settlement Endowment Trust awarded to the University of Oklahoma - Stephenson Cancer Center.  
12   The content is solely the responsibility of the authors and does not necessarily represent the official  
13   views of the Oklahoma Tobacco Settlement Endowment Trust.

1 **Supporting Information**

2 Additional equation S1, figures S1-S14, tables S1-S5, and methods and materials.

1      **References**  
2

3      (1) Singh, A. Eliciting B Cell Immunity against Infectious Diseases Using Nanovaccines. *Nat. Nanotechnol.* **2020**, *16* (1), 16–24. <https://doi.org/10.1038/s41565-020-00790-3>.

4      (2) Kranz, L. M.; Diken, M.; Haas, H.; Kreiter, S.; Loquai, C.; Reuter, K. C.; Meng, M.; Fritz,  
5      D.; Vascotto, F.; Hefesha, H.; Grunwitz, C.; Vormehr, M.; Hüsemann, Y.; Selmi, A.; Kuhn,  
6      A. N.; Buck, J.; Derhovanessian, E.; Rae, R.; Attig, S.; Diekmann, J.; Jabulowsky, R. A.;  
7      Heesch, S.; Hassel, J.; Langguth, P.; Grabbe, S.; Huber, C.; Türeci, Ö.; Sahin, U. Systemic  
8      RNA Delivery to Dendritic Cells Exploits Antiviral Defence for Cancer Immunotherapy.  
9      *Nature* **2016**, *534* (7607), 396–401. <https://doi.org/10.1038/nature18300>.

10     (3) Zilker, C.; Kozlova, D.; Sokolova, V.; Yan, H.; Epple, M.; Überla, K.; Temchura, V.  
11     Nanoparticle-Based B-Cell Targeting Vaccines: Tailoring of Humoral Immune Responses  
12     by Functionalization with Different TLR-Ligands. *Nanomedicine Nanotechnology, Biol.*  
13     *Med.* **2017**, *13* (1), 173–182. <https://doi.org/10.1016/j.nano.2016.08.028>.

14     (4) Irvine, D. J.; Read, B. J. Shaping Humoral Immunity to Vaccines through Antigen-  
15     Displaying Nanoparticles. *Curr. Opin. Immunol.* **2020**, *65*, 1–6.  
16     <https://doi.org/10.1016/j.coim.2020.01.007>.

17     (5) Kurosaki, T.; Kometani, K.; Ise, W. Memory B Cells. *Nat. Rev. Immunol.* **2015**, *15* (3),  
18     149–159. <https://doi.org/10.1038/nri3802>.

19     (6) Inoue, T.; Moran, I.; Shinnakasu, R.; Phan, T. G.; Kurosaki, T. Generation of Memory B  
20     Cells and Their Reactivation. *Immunol. Rev.* **2018**, *283* (1), 138–149.  
21     <https://doi.org/10.1111/imr.12640>.

22     (7) Tsoi, K. M.; Macparland, S. A.; Ma, X. Z.; Spetzler, V. N.; Echeverri, J.; Ouyang, B.; Fadel,  
23     S. M.; Sykes, E. A.; Goldaracena, N.; Kath, J. M.; Conneely, J. B.; Alman, B. A.; Selzner,  
24     M.; Ostrowski, M. A.; Adeyi, O. A.; Zilman, A.; McGilvray, I. D.; Chan, W. C. W.  
25     Mechanism of Hard-Nanomaterial Clearance by the Liver. *Nat. Mater.* **2016**, *15* (11), 1212–  
26     1221. <https://doi.org/10.1038/nmat4718>.

27     (8) Almeida, J. P. M.; Lin, A. Y.; Langsner, R. J.; Eckels, P.; Foster, A. E.; Drezek, R. A. In  
28     Vivo Immune Cell Distribution of Gold Nanoparticles in Naïve and Tumor Bearing Mice.  
29     *Small* **2014**, *10* (4), 812–819. <https://doi.org/10.1002/smll.201301998>.

30     (9) Martin, J. T.; Cottrell, C. A.; Antanasijevic, A.; Carnathan, D. G.; Cossette, B. J.; Enemuo,  
31     C. A.; Gebru, E. H.; Choe, Y.; Viviano, F.; Fischinger, S.; Tokatlian, T.; Cirelli, K. M.;  
32     Ueda, G.; Copps, J.; Schiffner, T.; Menis, S.; Alter, G.; Schieff, W. R.; Crotty, S.; King, N.  
33     P.; Baker, D.; Silvestri, G.; Ward, A. B.; Irvine, D. J. Targeting HIV Env Immunogens to B  
34     Cell Follicles in Nonhuman Primates through Immune Complex or Protein Nanoparticle  
35     Formulations. *npj Vaccines* **2020**, *5* (1). <https://doi.org/10.1038/s41541-020-00223-1>.

36     (10) Kato, Y.; Abbott, R. K.; Freeman, B. L.; Haupt, S.; Groschel, B.; Silva, M.; Menis, S.;  
37     Irvine, D. J.; Schieff, W. R.; Crotty, S. Multifaceted Effects of Antigen Valency on B Cell  
38     Response Composition and Differentiation In Vivo. *Immunity* **2020**, *53* (3), 548–563.e8.  
39     <https://doi.org/10.1016/j.immuni.2020.08.001>.

40     (11) Yang, W.; Wang, L.; Mettenbrink, E. M.; Deangelis, P. L.; Wilhelm, S. Nanoparticle  
41     Toxicology. *Annu. Rev. Pharmacol. Toxicol.* **2021**, *61*, 269–289.  
42     <https://doi.org/10.1146/annurev-pharmtox-032320-110338>.

43     (12) Narum, S. M.; Le, T.; Le, D. P.; Lee, J. C.; Donahue, N. D.; Yang, W.; Wilhelm, S. Passive  
44     Targeting in Nanomedicine: Fundamental Concepts, Body Interactions, and Clinical  
45     Potential. In *Nanoparticles for Biomedical Applications*; Elsevier, 2020; pp 37–53.

1 https://doi.org/10.1016/b978-0-12-816662-8.00004-7.

2 (13) Gottstein, C.; Wu, G.; Wong, B. J.; Zasadzinski, J. A. Precise Quantification of Nanoparticle  
3 Internalization. *ACS Nano* **2013**, *7* (6), 4933–4945. https://doi.org/10.1021/NN400243D.

4 (14) HyeRim Shin; Minjeong Kwak; Geol Lee, T.; Youn Lee, J. Quantifying the Level of  
5 Nanoparticle Uptake in Mammalian Cells Using Flow Cytometry. *Nanoscale* **2020**, *12* (29),  
6 15743–15751. https://doi.org/10.1039/D0NR01627F.

7 (15) Wu, Y.; Ali, M. R. K.; Dansby, K.; El-Sayed, M. A. Improving the Flow Cytometry-Based  
8 Detection of the Cellular Uptake of Gold Nanoparticles. *Anal. Chem.* **2019**.  
9 https://doi.org/10.1021/ACS.ANALCHEM.9B02248.

10 (16) Romeu, H. G.; Deville, S.; Salvati, A. Time- and Space-Resolved Flow-Cytometry of Cell  
11 Organelles to Quantify Nanoparticle Uptake and Intracellular Trafficking by Cells. *Small*  
12 **2021**, *17* (34), 2100887. https://doi.org/10.1002/SMLL.202100887.

13 (17) Zucker, R. M.; Massaro, E. J.; Sanders, K. M.; Degen, L. L.; Boyes, W. K. Detection of TiO<sub>2</sub>  
14 Nanoparticles in Cells by Flow Cytometry. *Cytom. Part A* **2010**, *77A* (7), 677–685.  
15 https://doi.org/10.1002/CYTO.A.20927.

16 (18) Elsaesser, A.; Taylor, A.; Yanés, G. S. de; McKerr, G.; Kim, E.-M.; O'Hare, E.; Howard,  
17 C. V. Quantification of Nanoparticle Uptake by Cells Using Microscopical and Analytical  
18 Techniques. *https://doi.org/10.2217/nnm.10.118* **2010**, *5* (9), 1447–1457.  
19 https://doi.org/10.2217/NNM.10.118.

20 (19) Suutari, T.; Silen, T.; Karaman, D. S.; Saari, H.; Desai, D.; Kerkelä, E.; Laitinen, S.;  
21 Hanzlikova, M.; Rosenholm, J. M.; Yliperttula, M.; Viitala, T. Real-Time Label-Free  
22 Monitoring of Nanoparticle Cell Uptake. *Small* **2016**, *12* (45), 6289–6300.  
23 https://doi.org/10.1002/SMLL.201601815.

24 (20) Yang, Y. S. S.; Atukorale, P. U.; Moynihan, K. D.; Bekdemir, A.; Rakhra, K.; Tang, L.;  
25 Stellacci, F.; Irvine, D. J. High-Throughput Quantitation of Inorganic Nanoparticle  
26 Biodistribution at the Single-Cell Level Using Mass Cytometry. *Nat. Commun.* **2017**, *8* (1),  
27 1–11. https://doi.org/10.1038/ncomms14069.

28 (21) Malysheva, A.; Ivask, A.; Doolette, C. L.; Voelcker, N. H.; Lombi, E. Cellular Binding,  
29 Uptake and Biotransformation of Silver Nanoparticles in Human T Lymphocytes. *Nat.*  
30 *Nanotechnol.* **2021** *168* **2021**, *16* (8), 926–932. https://doi.org/10.1038/s41565-021-00914-  
31 3.

32 (22) Pichaandi, J.; Tong, L.; Bouzekri, A.; Yu, Q.; Ornatsky, O.; Baranov, V.; Winnik, M. A.  
33 Liposome-Encapsulated NaLnF<sub>4</sub> Nanoparticles for Mass Cytometry: Evaluating  
34 Nonspecific Binding to Cells. *Chemistry of Materials*. **2017**, pp 4980–4990.  
35 https://doi.org/10.1021/acs.chemmater.7b01339.

36 (23) Donahue, N. D.; Kanapilly, S.; Stephan, C.; Marlin, M. C.; Francek, E. R.; Haddad, M.;  
37 Guthridge, J.; Wilhelm, S. Quantifying Chemical Composition and Reaction Kinetics of  
38 Individual Colloidally Dispersed Nanoparticles. *Nano Lett.* **2021**, *22* (1), 294–301.  
39 https://doi.org/10.1021/ACS.NANO lett.1C03752.

40 (24) Merrifield, R. C.; Stephan, C.; Lead, J. R. Quantification of Au Nanoparticle Biouptake and  
41 Distribution to Freshwater Algae Using Single Cell - ICP-MS. *Environ. Sci. Technol.* **2018**,  
42 *52* (4), 2271–2277. https://doi.org/10.1021/acs.est.7b04968.

43 (25) Gomez-Gomez, B.; Corte-Rodríguez, M.; Perez-Corona, M. T.; Bettmer, J.; Montes-Bayón,  
44 M.; Madrid, Y. Combined Single Cell and Single Particle ICP-TQ-MS Analysis to  
45 Quantitatively Evaluate the Uptake and Biotransformation of Tellurium Nanoparticles in  
46 Bacteria. *Anal. Chim. Acta* **2020**, *1128*, 116–128.

1 https://doi.org/10.1016/j.aca.2020.06.058.

2 (26) Álvarez-Fernández García, R.; Corte-Rodríguez, M.; Macke, M.; Leblanc, K. L.; Mester,  
3 Z.; Montes-Bayón, M.; Bettmer, J. Addressing the Presence of Biogenic Selenium  
4 Nanoparticles in Yeast Cells: Analytical Strategies Based on ICP-TQ-MS. *Analyst* **2020**,  
5 145 (4), 1457–1465. https://doi.org/10.1039/c9an01565e.

6 (27) Rasmussen, L.; Shi, H.; Liu, W.; Shannon, K. B. Quantification of Silver Nanoparticle  
7 Interactions with Yeast *Saccharomyces Cerevisiae* Studied Using Single-Cell ICP-MS.  
8 *Anal. Bioanal. Chem.* **2022**, No. 0123456789. https://doi.org/10.1007/s00216-022-03937-  
9 4.

10 (28) Corte Rodríguez, M.; Álvarez-Fernández García, R.; Blanco, E.; Bettmer, J.; Montes-  
11 Bayón, M. Quantitative Evaluation of Cisplatin Uptake in Sensitive and Resistant  
12 Individual Cells by Single-Cell ICP-MS (SC-ICP-MS). *Anal. Chem.* **2017**, 89 (21), 11491–  
13 11497. https://doi.org/10.1021/acs.analchem.7b02746.

14 (29) Cao, Y.; Feng, J.; Tang, L.; Yu, C.; Mo, G.; Deng, B. A Highly Efficient Introduction  
15 System for Single Cell- ICP-MS and Its Application to Detection of Copper in Single  
16 Human Red Blood Cells. *Talanta* **2020**, 206 (July 2019), 120174.  
17 https://doi.org/10.1016/j.talanta.2019.120174.

18 (30) Chun, K. H.; Lum, J. T. S.; Leung, K. S. Y. Dual-Elemental Analysis of Single Particles  
19 Using Quadrupole-Based Inductively Coupled Plasma-Mass Spectrometry. *Anal. Chim. Acta* **2022**, 1192, 339389. https://doi.org/10.1016/J.ACA.2021.339389.

20 (31) Wilhelm S, Bensen RC, Kothapali NR, et al. (2018) Quantification of gold nanoparticle  
21 uptake into cancer cells using single cell ICPMS. *PerkinElmer Appl Note*. 2018, 1-4.

22 (32) Yin, L.; Zhang, Z.; Liu, Y.; Gao, Y.; Gu, J. Recent Advances in Single-Cell Analysis by  
23 Mass Spectrometry. *Analyst* **2019**, 144 (3), 824–845. https://doi.org/10.1039/c8an01190g.

24 (33) Fousek, K.; Watanabe, J.; Joseph, S. K.; George, A.; An, X.; Byrd, T. T.; Morris, J. S.;  
25 Luong, A.; Martínez-Paniagua, M. A.; Sanber, K.; Navai, S. A.; Gad, A. Z.; Salsman, V.  
26 S.; Mathew, P. R.; Kim, H. N.; Wagner, D. L.; Brunetti, L.; Jang, A.; Baker, M. L.;  
27 Varadarajan, N.; Hegde, M.; Kim, Y.-M.; Heisterkamp, N.; Abdel-Azim, H.; Ahmed, N.  
28 CAR T-Cells That Target Acute B-Lineage Leukemia Irrespective of CD19 Expression.  
29 *Leuk.* **2020** 351 **2020**, 35 (1), 75–89. https://doi.org/10.1038/s41375-020-0792-2.

30 (34) Webster, B.; Xiong, Y.; Hu, P.; Wu, D.; Alabanza, L.; Orentas, R. J.; Dropulic, B.;  
31 Schneider, D. Self-Driving Armored CAR-T Cells Overcome a Suppressive Milieu and  
32 Eradicate CD19+ Raji Lymphoma in Preclinical Models. *Mol. Ther.* **2021**, 29 (9), 2691–  
33 2706. https://doi.org/10.1016/J.YMTHE.2021.05.006.

34 (35) Bjornson, Z. B.; Nolan, G. P.; Fantl, W. J. Single Cell Mass Cytometry for Analysis of  
35 Immune System Functional States. *Curr. Opin. Immunol.* **2013**, 25 (4), 484–494.  
36 https://doi.org/10.1016/J.COI.2013.07.004.

37 (36) Ijsselsteijn, M. E.; van der Breggen, R.; Farina Sarasqueta, A.; Koning, F.; de Miranda, N.  
38 F. C. C. A 40-Marker Panel for High Dimensional Characterization of Cancer Immune  
39 Microenvironments by Imaging Mass Cytometry. *Front. Immunol.* **2019**, 0 (OCT), 2534.  
40 https://doi.org/10.3389/FIMMU.2019.02534.

41 (37) Donahue, N. D.; Francek, E. R.; Kiyotake, E.; Thomas, E. E.; Yang, W.; Wang, L.;  
42 Detamore, M. S.; Wilhelm. Assessing Nanoparticle Colloidal Stability with Single-Particle  
43 Inductively Coupled Plasma Mass Spectrometry ( SP-ICP-MS ). *Anal. Bioanal. Chem.*  
44 **2020**, 412 (22), 5205-5216.

45 (38) Corte-Rodríguez, M.; Álvarez-Fernández, R.; García-Cancela, P.; Montes-Bayón, M.;

1 Bettmer, J. Single Cell ICP-MS Using on Line Sample Introduction Systems: Current  
2 Developments and Remaining Challenges. *TrAC Trends Anal. Chem.* **2020**, *132*, 116042.  
3 <https://doi.org/10.1016/J.TRAC.2020.116042>.

4 (39) Theiner, S.; Loehr, K.; Koellensperger, G.; Mueller, L.; Jakubowski, N. Single-Cell  
5 Analysis by Use of ICP-MS. *J. Anal. At. Spectrom.* **2020**, *35* (9), 1784–1813.  
6 <https://doi.org/10.1039/d0ja00194e>.

7 (40) Lum, J. T. S.; Leung, K. S. Y. Quantifying Silver Nanoparticle Association and Elemental  
8 Content in Single Cells Using Dual Mass Mode in Quadrupole-Based Inductively Coupled  
9 Plasma-Mass Spectrometry. *Anal. Chim. Acta* **2019**, *1061*, 50–59.  
10 <https://doi.org/10.1016/j.aca.2019.02.042>.

11 (41) Wang, H.; Wang, B.; Wang, M.; Zheng, L.; Chen, H.; Chai, Z.; Zhao, Y.; Feng, W. Time-  
12 Resolved ICP-MS Analysis of Mineral Element Contents and Distribution Patterns in  
13 Single Cells. *Analyst* **2015**, *140* (2), 523–531. <https://doi.org/10.1039/c4an01610f>.

14 (42) Finck, R.; Simonds, E. F.; Jager, A.; Krishnaswamy, S.; Sachs, K.; Fantl, W.; Pe'er, D.;  
15 Nolan, G. P.; Bendall, S. C. Normalization of Mass Cytometry Data with Bead Standards.  
16 *Cytometry Part A*. 2013, pp 483–494. <https://doi.org/10.1002/cyto.a.22271>.

17 (43) Olesik, J. W.; Gray, P. J. Considerations for Measurement of Individual Nanoparticles or  
18 Microparticles by ICP-MS: Determination of the Number of Particles and the Analyte Mass  
19 in Each Particle. *J. Anal. At. Spectrom.* **2012**, *27* (7), 1143–1155.  
20 <https://doi.org/10.1039/c2ja30073g>.

21 (44) Perrault, S.; C. W. Chan, W. Synthesis and Surface Modification of Highly  
22 Monodispersed, Spherical Gold Nanoparticles of 50–200 Nm. *J. Am. Chem. Soc.* **2009**, *131*  
23 (47), 17042–17043. <https://doi.org/10.1021/ja907069u>.

24 (45) Lee, J. C.; Donahue, N. D.; Mao, A. S.; Karim, A.; Komarneni, M.; Thomas, E. E.; Francek,  
25 E. R.; Yang, W.; Wilhelm, S. Exploring Maleimide-Based Nanoparticle Surface  
26 Engineering to Control Cellular Interactions. *ACS Appl. Nano Mater.* **2020**.  
27 <https://doi.org/10.1021/acsanm.9b02541>.

28 (46) Donahue, N. D.; Acar, H.; Wilhelm, S. Concepts of Nanoparticle Cellular Uptake,  
29 Intracellular Trafficking, and Kinetics in Nanomedicine. *Adv. Drug Deliv. Rev.* **2019**, *143*.  
30 <https://doi.org/10.1016/j.addr.2019.04.008>.

31 (47) Wang, F.; Chen, B.; Yan, B.; Yin, Y.; Hu, L.; Liang, Y.; Song, M.; Jiang, G. Scattered Light  
32 Imaging Enables Real-Time Monitoring of Label-Free Nanoparticles and Fluorescent  
33 Biomolecules in Live Cells. *J. Am. Chem. Soc.* **2019**, *141* (36), 14043–14047.  
34 <https://doi.org/10.1021/jacs.9b05894>.

35 (48) Yang, W.; Wang, L.; Fang, M.; Sheth, V.; Zhang, Y.; Holden, A. M.; Donahue, N. D.;  
36 Green, D. E.; Frickenstein, A. N.; Mettenbrink, E. M.; Schwemley, T. A.; Francek, E. R.;  
37 Haddad, M.; Hossen, M. N.; Mukherjee, S.; Wu, S.; DeAngelis, P. L.; Wilhelm, S.  
38 Nanoparticle Surface Engineering with Heparosan Polysaccharide Reduces Serum Protein  
39 Adsorption and Enhances Cellular Uptake. *Nano Lett.* **2022**, *22* (5), 2103–2111.  
40 <https://doi.org/10.1021/acs.nanolett.2c00349>.

41 (49) Cho, E. C.; Xie, J.; Wurm, P. A.; Xia, Y. Understanding the Role of Surface Charges in  
42 Cellular Adsorption versus Internalization by Selectively Removing Gold Nanoparticles on  
43 the Cell Surface with a I<sub>2</sub>/KI Etchant. *Nano Lett.* **2009**, *9* (3), 1080–1084.  
44 <https://doi.org/10.1021/nl803487r>.

45 (50) Sheth, V.; Wang, L.; Bhattacharya, R.; Mukherjee, P.; Wilhelm, S. Strategies for Delivering  
46 Nanoparticles across Tumor Blood Vessels. *Adv. Funct. Mater.* **2021**, *31* (8), 2007363.

1           <https://doi.org/10.1002/ADFM.202007363>.  
2